Drug Profile
Research programme: enzyme therapeutics - Spyre Therapeutics
Alternative Names: AEB 2109; AEB 3103; AECase/AEB3103; AEMase/AEB2109Latest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Aeglea Biotherapeutics
- Developer Spyre Therapeutics
- Class Antineoplastics; Enzymes
- Mechanism of Action Neutral amino acid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Homocystinuria in USA (Parenteral)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)